- Home
- PTHL vs CNTB Comparison
PTHL vs CNTB Comparison
Compare PTHL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- CNTB
- Stock Information
- Founded
- PTHL 1998
- CNTB 2012
- Country
- PTHL China
- CNTB United States
- Employees
- PTHL N/A
- CNTB N/A
- Industry
- PTHL
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- CNTB Health Care
- Exchange
- PTHL Nasdaq
- CNTB Nasdaq
- Market Cap
- PTHL 72.9M
- CNTB 68.5M
- IPO Year
- PTHL 2024
- CNTB 2021
- Fundamental
- Price
- PTHL $4.54
- CNTB $1.24
- Analyst Decision
- PTHL
- CNTB Strong Buy
- Analyst Count
- PTHL 0
- CNTB 1
- Target Price
- PTHL N/A
- CNTB $8.00
- AVG Volume (30 Days)
- PTHL 295.9K
- CNTB 26.7K
- Earning Date
- PTHL 11-11-2024
- CNTB 09-05-2024
- Dividend Yield
- PTHL N/A
- CNTB N/A
- EPS Growth
- PTHL N/A
- CNTB N/A
- EPS
- PTHL N/A
- CNTB N/A
- Revenue
- PTHL $572,291.00
- CNTB $24,116,000.00
- Revenue This Year
- PTHL N/A
- CNTB N/A
- Revenue Next Year
- PTHL N/A
- CNTB $63.90
- P/E Ratio
- PTHL N/A
- CNTB N/A
- Revenue Growth
- PTHL 2.32
- CNTB N/A
- 52 Week Low
- PTHL $3.32
- CNTB $0.68
- 52 Week High
- PTHL $6.45
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- CNTB 46.92
- Support Level
- PTHL N/A
- CNTB $1.22
- Resistance Level
- PTHL N/A
- CNTB $1.44
- Average True Range (ATR)
- PTHL 0.00
- CNTB 0.13
- MACD
- PTHL 0.00
- CNTB -0.02
- Stochastic Oscillator
- PTHL 0.00
- CNTB 9.68
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.